# A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

> **NCT05013229** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 679 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** IcoSema
- **DRUG:** Insulin glargine
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT05013229
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-30
- **Primary completion:** 2023-11-14
- **Final completion:** 2023-11-14
- **Target enrollment:** 679 (ACTUAL)
- **Last updated:** 2025-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05013229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05013229, "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05013229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*